Key result
Therapeutic antibodies and gene therapy undergo clinical and preclinical testing for managing lupus erythematosus.
This review summarizes the development and potential of therapeutic antibodies and gene therapy for managing lupus erythematosus.
Should not yet change lupus management; leaves open the need for confirmatory trials of these emerging therapies.
Lupus erythematosus is a chronic autoimmune inflammatory disease with largely unknown etiopathogenesis and no known cure. However, key steps in its pathophysiology have been recognized and targeted by specific therapeutic techniques. Human patients and murine models of lupus erythematosus manifest a wide range of immunological abnormalities. Therapeutic antibodies, which affect the activation of potentially autoreactive B cells, have been developed and are being tested in clinical trials. Preclinical studies have provided proof of concept for the feasibility and efficacy of gene therapy in human lupus erythematosus. In this article, we briefly review the clinical characteristics and immunological abnormalities of lupus erythematosus and summarize recent studies on the use of therapeutic antibodies and gene therapy for the management of human lupus erythematosus.
No takes yet. Share an insight, caveat, or question.
Neumann et al. (2007) conducted a review in Lupus erythematosus. Biologicals (therapeutic antibodies and gene therapy) was evaluated. Therapeutic antibodies and gene therapy are being developed and tested in clinical and preclinical studies for the management of human lupus erythematosus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: